In two Phase 1 studies in healthy volunteers, VE202 was generally safe and well tolerated at all doses and demonstrated durable and dose-dependent colonization. Vedanta expects to begin a Phase 2 study in IBD patients in the next 12 months.

For additional study information, please visit Clinicaltrials.gov:

https://clinicaltrials.gov/ct2/show/NCT03723746

https://clinicaltrials.gov/ct2/show/NCT03931447